Monday 15 June 2026

The Pharma Letter Podcast — Episode 20 — Galapagos update—with CEO Paul Stoffels

Biotechnology
Simon Wentworth
2 February 2023
2-2

More on this story...

Biotechnology
R&D U-turn sees Galapagos ditching liver and kidney programs
4 November 2022
Biotechnology
Belgian biotech Galapagos goes on a spending spree
22 June 2022
Biotechnology
NICE recommends Galapagos' Jyseleca in UC
1 June 2022
Biotechnology
Strategic overhaul continues apace at Galapagos, with new R&D deal
31 March 2023


Company News Directory



Companies featured in this story

More ones to watch >




Today's issue

Vivoryon’s kidney reset: CEO Frank Weber on the company’s new focus
Biotechnology
Vivoryon’s kidney reset: CEO Frank Weber on the company’s new focus
15 June 2026
Pharmaceutical
Grifols launches Fesilty in USA for rare bleeding disorder
15 June 2026
Biotechnology
Elicio Thera tanks on disappointing Phase II AMPLIFY-7P study
15 June 2026
Pharmaceutical
Two-year data bolster Neurocrine’s Crenessity case in pediatric CAH
15 June 2026
Biotechnology
J&J’s Talvey combo cuts progression risk in earlier myeloma setting
15 June 2026
Pharmaceutical
Pharmstandard to build large-scale complex for production of live vaccines
15 June 2026
Biotechnology
Positive Phase III results for Intellia’s lonvo-z
15 June 2026


Company Spotlight

Avidity Biosciences
A San Diego-based biotechnology company that pioneered muscle-targeted RNA delivery through its proprietary Antibody Oligonucleotide Conjugate platform, Avidity Biosciences was acquired by Novartis in February 2026 for approximately $12 billion.


More Features in Biotechnology

Vivoryon’s kidney reset: CEO Frank Weber on the company’s new focus
15 June 2026
Elicio Thera tanks on disappointing Phase II AMPLIFY-7P study
15 June 2026
J&J’s Talvey combo cuts progression risk in earlier myeloma setting
15 June 2026
Positive Phase III results for Intellia’s lonvo-z
15 June 2026


Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze